Also, immunohistochemical (IHC) analyses identify the presence of biomarkers as an integral part of correct diagnosis, where detection of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu is routinely used to provide both prognostic and predictive information necessary for the management of patients with breast cancer [4]. The gene discussed is ERBB2; the disease is breast carcinoma.